Research Topics
| Cynthia LemereSummaryAffiliation: Harvard University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Intraneuronal Abeta42 accumulation in Down syndrome brainChica Mori
Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
Amyloid 9:88-102. 2002..We conclude that Abeta42 accumulates intracellularly prior to extracellular Abeta deposition in Down syndrome, and that subsequent maturation of extracellular Abeta deposits elicits inflammatory responses andprecedes NFTs...
Increased DJ-1 expression under oxidative stress and in Alzheimer's disease brainsStephanie Baulac
Center for Neurologic Diseases, Department of Neurology, Brigham and Women s Hospital, Harvard Medical School, Harvard University, Boston, MA 02115, USA
Mol Neurodegener 4:12. 2009..Therefore, our results strongly suggest that DJ-1 expression is not necessary during zebrafish development but can be induced in zebrafish exposed to oxidative stress and is present in human AD brains...- Osteopetrotic (op/op) mice have reduced microglia, no Abeta deposition, and no changes in dopaminergic neuronsYoichi Kondo
Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706, USA
J Neuroinflammation 4:31. 2007..The purpose of these studies was to confirm this and to determine if the lack of CSF-1 affects the development of dopaminergic neurons and the expression of CD200, a known microglial inhibitory protein... - Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's diseaseRandall J Bateman
Department of Neurology, Washington University School of Medicine, 660 S, Euclid, Campus Box 8111, St Louis, MO 63110, USA
Alzheimers Res Ther 3:1. 2011..Clinical trials in autosomal-dominant Alzheimer's disease may test the amyloid hypothesis, determine the timing of treatment, and lead the way to Alzheimer's disease prevention... - Developing novel immunogens for a safe and effective Alzheimer's disease vaccineCynthia A Lemere
Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
Prog Brain Res 175:83-93. 2009..It is hoped that these novel immunogens will enhance Abeta antibody generation across a broad population and avoid the adverse events seen in the earlier clinical trial... - A beneficial role for IL-1 beta in Alzheimer disease?Cynthia A Lemere
Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
J Clin Invest 117:1483-5. 2007..Thus, manipulation of the immune system may be a potential therapeutic approach to protect against AD, although further studies are needed to understand all of the downstream effects of this manipulation... - Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervetCynthia A Lemere
Center for Neurologic Diseases, HIM 622, Department of Neurology, Brigham and Women s Hospital and Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02215, USA
Am J Pathol 165:283-97. 2004..The findings further support Abeta immunotherapy as a potential prevention and treatment of AD... - Novel Abeta immunogens: is shorter better?Cynthia A Lemere
Center for Neurologic Diseases, Department of Neurology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115 USA
Curr Alzheimer Res 4:427-36. 2007..We remain optimistic about the potential of such a vaccine for prevention and treatment of AD... - Can Alzheimer disease be prevented by amyloid-beta immunotherapy?Cynthia A Lemere
Center for Neurologic Diseases, Department of Neurology, Brigham and Women s Hospital, New Research Building 636F, Boston, MA 02115, USA
Nat Rev Neurol 6:108-19. 2010..Biomarkers for AD and imaging technology have improved greatly over the past 10 years and, in the future, might be used to identify presymptomatic, at-risk individuals who might benefit from Abeta immunization... - Amyloid-beta immunotherapy for the prevention and treatment of Alzheimer disease: lessons from mice, monkeys, and humansCynthia A Lemere
Center for Neurologic Diseases, Department of Neurology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
Rejuvenation Res 9:77-84. 2006..The authors remain optimistic about the potential of such a vaccine for the prevention and treatment of AD... - Short amyloid-beta (Abeta) immunogens reduce cerebral Abeta load and learning deficits in an Alzheimer's disease mouse model in the absence of an Abeta-specific cellular immune responseMarcel Maier
Center for Neurological Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
J Neurosci 26:4717-28. 2006..Thus, our novel immunogens show promise for future AD vaccines... - Dendrimeric Abeta1-15 is an effective immunogen in wildtype and APP-tg miceTimothy J Seabrook
Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, United States
Neurobiol Aging 28:813-23. 2007..Anti-Abeta antibodies bound monomeric, oligomeric, and fibrillar Abeta. Our data suggest that dAbeta1-15 may be an effective and potentially safer immunogen for Alzheimer's disease (AD) vaccination... - Effects of huperzine A on amyloid precursor protein processing and beta-amyloid generation in human embryonic kidney 293 APP Swedish mutant cellsYing Peng
Center for Neurologic Diseases, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts 02115, USA
J Neurosci Res 84:903-11. 2006..Our data suggest alternative pharmacological mechanisms of Hup A relevant to the treatment of Alzheimer's disease... - Developing novel immunogens for an effective, safe Alzheimer's disease vaccineMarcel Maier
Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
Neurodegener Dis 2:267-72. 2005..These data together with published reports from several other groups suggest that a safe, active A beta vaccine is a tenable goal... - Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memoryGanesh M Shankar
Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, 77 Avenue Louis Pasteur, Boston, Massachusetts 02115, USA
Nat Med 14:837-42. 2008..We conclude that soluble Abeta oligomers extracted from Alzheimer's disease brains potently impair synapse structure and function and that dimers are the smallest synaptotoxic species... - Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic miceMarcel Maier
Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
J Neurosci 28:6333-41. 2008..Our results suggest a beneficial role for complement C3 in plaque clearance and neuronal health as well as in modulation of the microglia phenotype... - Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunizationIgor Klyubin
Institute of Neuroscience and Department of Pharmacology and Therapeutics, Trinity College, Dublin 2, Ireland
J Neurosci 28:4231-7. 2008..Abeta monomer isolated from human CSF did not affect long-term potentiation. These results strongly support a strategy of passive immunization against soluble Abeta oligomers in early Alzheimer's disease... 
Cerebral amyloid-beta protein accumulation with aging in cotton-top tamarins: a model of early Alzheimer's disease?Cynthia A Lemere
Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
Rejuvenation Res 11:321-32. 2008..Phospho-tau labeled dystrophic neurites and tangles, typically present in human AD, were absent in the tamarins. In conclusion, tamarins may represent a model of early AD pathology...- l-3-n-Butylphthalide ameliorates beta-amyloid-induced neuronal toxicity in cultured neuronal cellsYing Peng
Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, No 1, Xiannongtan Street, Xuanwu District, Beijing 100050, China
Neurosci Lett 434:224-9. 2008..Our results suggest that l-NBP may protect neurons against Abeta-induced neurotoxicity via inhibiting tau protein hyperphosphorylation... - Minocycline affects microglia activation, Abeta deposition, and behavior in APP-tg miceTimothy J Seabrook
Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Glia 53:776-82. 2006..Therefore, anti-inflammatory therapies to suppress microglial activation or function may reduce cytokine production but enhance Abeta plaque formation early in AD... - The generation and characterization of potentially therapeutic Abeta antibodies in mice: differences according to strain and immunization protocolEdward T Spooner
Center for Neurologic Diseases, Brigham and Woman's Hospital and Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115-5716, USA
Vaccine 21:290-7. 2002..Currently there is no effective therapy for Alzheimer's disease; thus if Abeta immunization proves effective, it would be a significant step in the prevention and/or treatment of this devastating disease... - Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvantsCynthia A Lemere
Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Neurobiol Aging 23:991-1000. 2002..This new and improved Abeta vaccine protocol is now being tested in AD mouse models with the expectation that higher Abeta antibody titers may be more effective in reducing cerebral Abeta levels... - Abeta1-15 is less immunogenic than Abeta1-40/42 for intranasal immunization of wild-type mice but may be effective for "boosting"Jodi F Leverone
Department of Neurology, Center for Neurologic Diseases, Harvard Institutes of Medicine 622, Brigham and Women's Hospital, 77 Avenue Louis Pasteur, Boston, MA 02115-5716, USA
Vaccine 21:2197-206. 2003..The adjuvants were well-tolerated in the mice. Thus, Abeta1-15 may have potential as a safer, more cost-effective "boosting" immunogen than the full-length Abeta peptide for chronic, active Abeta immunization... - Amyloid-beta immunization in Alzheimer's disease transgenic mouse models and wildtype miceCynthia A Lemere
Department of Neurology, Center for Neurologic Diseases, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
Neurochem Res 28:1017-27. 2003..Studies in AD mouse models and wildtype mice may help elucidate the mechanism for these unwanted side effects and will be useful for testing newer, safer vaccines for future use in human clinical trials... - Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP miceCynthia A Lemere
Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Neurobiol Dis 14:10-8. 2003..Most of the Abeta in the serum of the immunized mice was bound to antibodies. We conclude that following active immunization, anti-Abeta antibodies sequester serum Abeta and may increase central nervous system to serum Abeta clearance... - APP processing is regulated by cytoplasmic phosphorylationMing-Sum Lee
Department of Pathology, Harvard Medical School and Howard Hughes Medical Institute, 200 Longwood Ave, Boston, MA 02115, USA
J Cell Biol 163:83-95. 2003..Together, these results suggest that T668 phosphorylation may facilitate the BACE1 cleavage of APP to increase Abeta generation... - Alzheimer's Abeta vaccination of rhesus monkeys (Macaca mulatta)Sam Gandy
Farber Institute for Neurosciences, Thomas Jefferson University, Philadelphia, PA 19107, USA
Mech Ageing Dev 125:149-51. 2004..These data support the use of non-human primates to model certain phenomena associated with vaccination of humans with aggregated Alzheimer's Abeta... - A seed for Alzheimer amyloid in the brainHideki Hayashi
Department of Dementia Research, National Institute for Longevity Sciences, Obu 474-8522, Japan
J Neurosci 24:4894-902. 2004..These results imply a mechanism underlying the onset of AD and suggest that an endogenous seed can be a target of therapeutic strategy... - Alzheimer A beta vaccination of rhesus monkeys (Macaca mulatta)Sam Gandy
Farber Institute for Neurosciences, Thomas Jefferson University, 900 Walnut St, Suite 467, Philadelphia, PA 19107, USA
Alzheimer Dis Assoc Disord 18:44-6. 2004..These data support the use of nonhuman primates to model certain phenomena associated with vaccination of humans with aggregated Alzheimer A beta... - Species-specific immune response to immunization with human versus rodent A beta peptideTimothy J Seabrook
Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
Neurobiol Aging 25:1141-51. 2004..Therefore, immunizing APP-tg and non-tg mice with rodent A beta resulted in a species-specific humoral response with modest T cell reactivity... - Reduced beta-amyloid production and increased inflammatory responses in presenilin conditional knock-out miceVassilios Beglopoulos
Center for Neurologic Diseases, Brigham and Women s Hospital, Program in Neuroscience, Harvard Medical School, Boston, Massachusetts 02115, USA
J Biol Chem 279:46907-14. 2004..These results indicate that the memory impairment and neurodegeneration in PS cDKO mice are not caused by Abeta accumulation and that loss of PS function leads to differential up-regulation of inflammatory markers in the cerebral cortex... - Differences in the immune response to long term Abeta vaccination in C57BL/6 and B6D2F1 miceTimothy J Seabrook
Center for Neurologic Diseases, Brigham and Women's Hospital, and Harvard Medical School, NRB 636F, Boston, MA 02115, USA
Vaccine 22:4075-83. 2004..These data may help explain some differences observed in Abeta immunization studies in mice of various genetic backgrounds and aid in the design of Abeta vaccines... - Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivoIgor Klyubin
Trinity College Institute of Neuroscience, Department of Pharmacology and Therapeutics, Trinity College, Dublin 2, Ireland
Nat Med 11:556-61. 2005.... - Modulation of the humoral and cellular immune response in Abeta immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT(R192G)Marcel Maier
Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
Vaccine 23:5149-59. 2005..In conclusion, MPL/TDM, in addition to LT(R192G), is an effective adjuvant when combined with Abeta40/42 and may aid in the design of Abeta immunotherapy... - The 8th International Conference on Alzheimer's Disease and Related Disorders, July 20-25, 2002, Stockholm, SwedenW Taylor Kimberly
Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Harvard Institutes of Medicine, 77 Avenue Louis Pasteur, Boston, MA 02115, USA
Amyloid 10:51-61. 2003
Research Grants
- Mucosal Abeta Vaccination: Modulating the Immune ResponseCynthia A Lemere; Fiscal Year: 2010..We are working towards a safer active Abeta vaccine and exploring mechanisms involving complement and its receptors. ..
- Mucosal Abeta Vaccination: Modulating the Immune ResponseCynthia Lemere; Fiscal Year: 2007..Lay Summary: Abeta immunotherapy has the potential to prevent and treat Alzheimer's disease but must be made safer. We are working towards a safer active Abeta vaccine and exploring mechanisms involving complement and its receptors. ..
- Mucosal ABeta Vaccination: Modulating the Immune Respon*Cynthia Lemere; Fiscal Year: 2005....
- Mucosal Abeta Vaccination: Modulating the Immune ResponseCynthia Lemere; Fiscal Year: 2009..We are working towards a safer active Abeta vaccine and exploring mechanisms involving complement and its receptors. ..